2Vacca A, Ribatti D, Presta M, et al. Bonemarrow neovascularization,plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma[J]. Blood,1999, 93(9):3064-3073.
3Dimopoulos M A, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's mcroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone[J]. Semin Oncnl, 2003, 30(2):265-269.
4Bellamy W, Richter L, Frutigar Y, et al. Expression of vascular endothelial growth factor and its receptor in hematological malignancies[J]. Cancer Res, 1999, 59(3):728-733.
5Quilitz R, Pharm D. Thalidomide in oncology: the peril and the promise[J]. Cancer Control, 1999, 6(5):483-495.
6Dimopoulos M A, Zomas A, Viniou N A, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide[J]. J Clin Oncol, 2001, 19(16):3593-3601.
7Coleman M, Leonard J, Lyons L, et al. Treatment of Waldenstrom's mcroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone[J]. Semin Oncnl, 2003, 30(2):270-274.
二级参考文献21
1Singhal S;Mehta J;Desikan R.Anti-tumor activity of thalidomide in refractory multiple myeloma[J],1999(21).
2Quilitz R;Pharm D.Thalidomide in oncology:the peril and the promise,1999(05).
3Figg WD;Raje S;Bauer KS.Pharmacokinetics of thalidomide in an elderly prostate cancer population[J],1999(01).
4D' Amato RJ;Loughnan MS;Flynn E.Thalidomide is an inhibitorof angiogenesis,1991.
5Verheul HM;Panigraphy D;Yuan J.Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits,1999(01).
6Liu J;Razani B;Tang S.Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells angiogenisis inhibitors block vascular endothelial growth factor-induced down-regulation of cavolin-1[J],1999(22).
7Pierres A;Benoliel AM;Bongrand P.Adhesion molecules and cancer,1999(12).
